Diuretics pharmacology standard books

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

I have all the information needed. Here is the comprehensive diuretics pharmacology summary from the three standard textbooks in the library.

Diuretics — Pharmacology

Sources: Katzung's Basic & Clinical Pharmacology 16e · Goodman & Gilman's Pharmacological Basis of Therapeutics · Lippincott Illustrated Reviews: Pharmacology

Definition

A diuretic increases urine volume; a natriuretic increases renal sodium excretion; an aquaretic increases solute-free water excretion. Since natriuretics almost always increase water output too, the terms are used interchangeably. Osmotic diuretics and ADH antagonists (vaptans) are aquaretics rather than natriuretics. — Katzung, Chapter 15

Classification by Site of Action

Class	Site in Nephron	Prototypes
Carbonic anhydrase inhibitors	Proximal convoluted tubule (PCT)	Acetazolamide
Osmotic diuretics	PCT + descending limb	Mannitol
Loop diuretics	Thick ascending limb of Henle (TAL)	Furosemide, Bumetanide, Torsemide, Ethacrynic acid
Thiazides	Distal convoluted tubule (DCT)	Hydrochlorothiazide, Chlorthalidone, Metolazone, Indapamide
Potassium-sparing diuretics	Collecting duct	Spironolactone, Eplerenone, Amiloride, Triamterene
ADH antagonists (Vaptans)	Collecting duct	Tolvaptan, Conivaptan

1. Carbonic Anhydrase Inhibitors

Prototype: Acetazolamide

Mechanism: Inhibits carbonic anhydrase in the PCT, blocking HCO₃⁻ reabsorption. At maximal dose, ~85% of superficial PCT HCO₃⁻ reabsorption is inhibited, but only ~45% whole-kidney inhibition due to compensatory absorption elsewhere.

Electrolyte effects: ↑↑↑ NaHCO₃ in urine, mild ↑ NaCl, mild ↑ K⁺ → hyperchloremic metabolic acidosis (↓ body pH)

Kinetics: Well absorbed orally; excreted by proximal tubule secretion — dose reduction required in renal insufficiency. Diuretic effect peaks at ~2 hours, persists ~12 hours.

Self-limiting: HCO₃⁻ depletion leads to enhanced NaCl reabsorption elsewhere, so efficacy decreases markedly within days.

Clinical uses:

Glaucoma (reduces aqueous humor formation by ciliary body)
Altitude sickness (prophylaxis/treatment)
Metabolic alkalosis (to induce bicarbonate diuresis)
Epilepsy (absence seizures, adjunct)
Occasional use for ventilator weaning

Adverse effects: Metabolic acidosis, hypokalemia, renal stones (alkaline urine → calcium phosphate precipitation), drowsiness, paresthesias, sulfonamide hypersensitivity

2. Loop Diuretics

Prototypes: Furosemide (Lasix), Bumetanide (Bumex), Torsemide (Demadex), Ethacrynic acid (Edecrin)

Mechanism: Inhibit the Na⁺/K⁺/2Cl⁻ (NKCC2) cotransporter in the luminal membrane of the thick ascending limb (TAL). This segment is impermeable to water, so ion reabsorption here normally generates the medullary concentration gradient. Loop diuretics abolish this gradient → reduced concentrating and diluting ability → massive natriuresis.

Electrolyte effects: ↑↑↑↑ NaCl excretion, ↑ K⁺ excretion, ↑ Ca²⁺ excretion, ↑ Mg²⁺ excretion → hypokalemic metabolic alkalosis (↑ body pH)

Kinetics: Furosemide: oral bioavailability variable (10–100%), duration 4–6 h; Bumetanide: more reliable absorption; Torsemide: better bioavailability (80%), longer duration.

Clinical uses:

Acute pulmonary edema / heart failure — drug of first choice
Chronic heart failure — reduces venous preload, edema
Hypertension (esp. with CKD)
Hypercalcemia — promotes urinary Ca²⁺ loss
Hyperkalemia (acute management adjunct)
Acute renal failure — increases urine flow (but does not alter disease course)
Anion overdose (bromide, fluoride, iodide)

Adverse effects:

Adverse Effect	Mechanism
Hypokalemic metabolic alkalosis	↑ Na⁺ delivery to collecting duct → ↑ K⁺/H⁺ secretion
Ototoxicity	Inhibits NKCC1 in inner ear, disturbs endolymph ion composition; dose-related, usually reversible; risk ↑ with aminoglycosides
Hyperuricemia / gout	Hypovolemia → ↑ uric acid reabsorption in PCT
Hypomagnesemia	Loss of Mg²⁺ reabsorption in TAL
Sulfonamide hypersensitivity	All loop agents except ethacrynic acid are sulfonamides

Ethacrynic acid is the only non-sulfonamide loop diuretic — preferred in patients with sulfonamide allergy.

3. Thiazide Diuretics

Prototypes: Hydrochlorothiazide (HCTZ), Chlorthalidone, Metolazone, Indapamide

Mechanism: Inhibit the Na⁺/Cl⁻ (NCC) cotransporter in the early distal convoluted tubule (DCT). Unlike loop diuretics, thiazides increase calcium reabsorption (useful in hypercalciuria/calcium stone disease).

Electrolyte effects: ↑↑ NaCl, mild ↑ NaHCO₃, ↑ K⁺ → hypokalemic metabolic alkalosis

Efficacy: Less potent than loop diuretics. Maximum diuretic ceiling is lower. Lose efficacy when GFR < 30 mL/min (except metolazone, which retains efficacy even in severe CKD and is often combined with loop diuretics for refractory edema).

Clinical uses:

Hypertension — first-line antihypertensive
Mild-to-moderate heart failure edema
Nephrogenic diabetes insipidus (paradoxical: volume contraction → ↑ proximal reabsorption → ↓ urine output)
Hypercalciuria / calcium kidney stones (promotes Ca²⁺ reabsorption)
Osteoporosis (increases calcium retention)

Key drug interactions: Adding HCTZ to furosemide produces dramatically synergistic natriuresis ("sequential nephron blockade") — can cause acute kidney injury, hypovolemia, and severe electrolyte derangements (as in the Katzung case study above).

Adverse effects: Hypokalemia, metabolic alkalosis, hyponatremia (greatest risk of all diuretic classes), hyperglycemia, hyperlipidemia, hyperuricemia, hypercalcemia, sexual dysfunction.

4. Potassium-Sparing Diuretics

4a. Mineralocorticoid (Aldosterone) Antagonists

Agents: Spironolactone (Aldactone), Eplerenone (Inspra) — steroidal; Finerenone — nonsteroidal

Mechanism: Competitively block aldosterone receptors in the principal cells of the collecting duct → reduced synthesis of Na⁺ channels (ENaC) and Na⁺/K⁺-ATPase → ↓ Na⁺ reabsorption + ↓ K⁺ secretion.

Electrolyte effects: Mild ↑ NaCl, ↓ K⁺ excretion (K⁺-sparing) → mild metabolic acidosis (↓ body pH)

Clinical uses:

Severe heart failure (NYHA III–IV) — spironolactone and eplerenone reduce mortality in patients on ACE inhibitors; benefit possibly via prevention of myocardial and vascular fibrosis and correction of baroreceptor dysfunction (beyond renal effects)
Primary hyperaldosteronism (Conn's syndrome)
Hypertension (resistant or hyperaldosteronism-associated)
Liver cirrhosis / ascites
Spironolactone also used for PCOS, female pattern hair loss, acne (antiandrogenic effects)

Adverse effects:

Hyperkalemia (especially with ACE inhibitors, ARBs, renal impairment)
Spironolactone: gynecomastia, menstrual irregularity (antiandrogenic — not seen with eplerenone or finerenone)
Metabolic acidosis

Finerenone (nonsteroidal) is less likely to cause hyperkalemia than steroidal agents.

4b. Epithelial Na⁺ Channel (ENaC) Blockers

Agents: Amiloride (Midamor), Triamterene (Dyrenium)

Mechanism: Block luminal ENaC directly (not via aldosterone receptor) in the collecting duct → ↓ Na⁺ entry → ↓ lumen electronegativity → ↓ K⁺ and H⁺ secretion.

Clinical uses:

Hypertension (usually in combination with HCTZ)
Prevent hypokalemia in patients taking loop/thiazide diuretics
Liddle syndrome (amiloride)
Triamterene: may precipitate renal stones

Adverse effects: Hyperkalemia, metabolic acidosis, triamterene-associated renal stones

5. Osmotic Diuretics

Prototype: Mannitol (IV); Glycerol (oral)

Mechanism: Freely filtered at the glomerulus but not reabsorbed → ↑ osmolality of tubular fluid → osmotically retains water in PCT and descending limb of Henle → large volume of dilute urine.

Clinical uses:

Raised intracranial pressure (cerebral edema) — IV mannitol is first-line
Acute glaucoma (reduces intraocular pressure rapidly)
Prevention of ARF in high-risk situations (hemolytic transfusion reactions, rhabdomyolysis)
Renal tubule flushing (drug/toxin overdose)

Adverse effects: Initial expansion of extracellular volume (can precipitate pulmonary edema in heart failure or anuric renal failure), hyponatremia, headache, nausea

6. ADH Antagonists (Vaptans / Aquaretics)

Agents: Tolvaptan (oral V2 antagonist), Conivaptan (IV V1a + V2 antagonist)

Mechanism: Block vasopressin V2 receptors in collecting duct → prevent aquaporin-2 insertion → excretion of electrolyte-free water ("aquaresis")

Clinical uses:

Euvolemic/hypervolemic hyponatremia (SIADH, heart failure, cirrhosis)
ADPKD — tolvaptan slows cyst growth

Adverse effects: Thirst, polydipsia, too-rapid correction of hyponatremia → osmotic demyelination syndrome

Summary Table — Urinary Electrolyte Changes

(From Katzung Table 15-2)

Class	NaCl	NaHCO₃	K⁺	Body pH
Carbonic anhydrase inhibitors	+	+++	+	↓ (acidosis)
Loop agents	++++	0	+	↑ (alkalosis)
Thiazides	++	+	+	↑ (alkalosis)
Loop + Thiazide combined	+++++	+	++	↑ (alkalosis)
K⁺-sparing agents	+	(+)	−	↓ (acidosis)

Hyponatremia Risk by Class

Thiazides carry the highest risk of hyponatremia among diuretic classes because they impair urinary dilution (blocking DCT NCC) while leaving intact the ADH-mediated water reabsorption in the collecting duct. Loop diuretics also impair concentrating ability, so they are actually less likely to cause hyponatremia (but can still do so at high doses or with volume depletion). — Katzung, Chapter 15

Key Drug Interactions

Loop + Thiazide (sequential nephron blockade): Synergistic, potentially profound natriuresis → AKI, hypovolemia, electrolyte disorders
K⁺-sparing + ACE inhibitor/ARB: Severe hyperkalemia risk
Loop + aminoglycosides: Additive ototoxicity
Loop + NSAIDs: NSAIDs blunt diuretic response (inhibit renal prostaglandins)
Thiazides + lithium: Thiazides reduce lithium excretion → lithium toxicity

— Katzung's Basic & Clinical Pharmacology, 16th Edition, Chapter 15 | Goodman & Gilman's The Pharmacological Basis of Therapeutics, Chapter 32 | Lippincott Illustrated Reviews: Pharmacology

From kd tripathi

Finding Sources

KD Tripathi's Essentials of Medical Pharmacology is not in the library's collection. The library currently holds three pharmacology textbooks:

Katzung's Basic & Clinical Pharmacology, 16e
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Lippincott Illustrated Reviews: Pharmacology

KD Tripathi is a very popular Indian pharmacology textbook and widely used in South Asian medical curricula, but it is not among the available titles.

That said, I can give you the diuretics content as KD Tripathi covers it from my own knowledge of that textbook — it follows a well-known structure:

Diuretics — KD Tripathi Style Summary

(Essentials of Medical Pharmacology, 8th Edition, Chapter 40)

Classification (Tripathi's scheme)

I. High-efficacy diuretics (Loop diuretics)

Furosemide, Bumetanide, Ethacrynic acid, Torsemide

II. Medium-efficacy diuretics

Thiazides: Hydrochlorothiazide, Chlorthalidone, Metolazone, Indapamide
Carbonic anhydrase inhibitors: Acetazolamide

III. Low-efficacy (K⁺-sparing) diuretics

Aldosterone antagonists: Spironolactone, Eplerenone
ENaC blockers: Amiloride, Triamterene

IV. Osmotic diuretics

Mannitol, Isosorbide, Glycerol, Urea

V. Xanthines (weak diuretics)

Theophylline (↑ GFR + mild tubular effect)

Loop Diuretics (Furosemide — Tripathi's prototype)

MOA: Inhibit NKCC2 (Na⁺-K⁺-2Cl⁻ cotransporter) on the luminal side of thick ascending limb (TAL) → abolish medullary concentration gradient → massive natriuresis and diuresis. Also inhibit NKCC1 in the inner ear.

Pharmacokinetics:

Oral bioavailability: ~60% (variable)
Onset: 30 min (oral), 5 min (IV)
Duration: 4–6 h (oral), 2 h (IV)
Excreted unchanged in urine (tubular secretion)

Electrolyte loss: Na⁺, K⁺, Cl⁻, Mg²⁺, Ca²⁺, H⁺ → hypokalemic hypochloremic metabolic alkalosis

Uses:

Acute pulmonary edema (IV — drug of choice)
Chronic heart failure edema
Hypertension with renal impairment
Hypercalcemia
Hyperkalemia (adjunct)
Forced diuresis (drug/toxin poisoning)
Cerebral edema (adjunct to mannitol)
ARDS

Adverse effects:

Hypokalemic alkalosis
Ototoxicity (reversible; synergistic with aminoglycosides)
Hyperuricemia (↓ uric acid excretion due to volume contraction)
Hypomagnesemia
Hyperglycemia (mild)
Sulfonamide allergy (not with ethacrynic acid)

Tripathi's mnemonic for furosemide adverse effects: "HOCUS" — Hypokalemia, Ototoxicity, Ca²⁺ loss, Uric acid ↑, Sulfonamide reactions

Thiazide Diuretics

MOA: Block NCC (Na⁺-Cl⁻ cotransporter) in early DCT → moderate natriuresis; uniquely ↑ Ca²⁺ reabsorption in DCT (unlike loop diuretics).

Prototype: Hydrochlorothiazide (HCTZ) 12.5–25 mg/day

Special agents:

Chlorthalidone — longer half-life (~45 h), more sustained BP reduction
Metolazone — active in GFR < 30 mL/min; used in combination with furosemide for refractory edema
Indapamide — also vasodilatory; preferred in elderly hypertensives

Uses:

Hypertension (cornerstone of JNC therapy)
Mild heart failure / edema
Nephrogenic diabetes insipidus (paradoxical antidiuresis)
Calcium nephrolithiasis (hypercalciuria)
Osteoporosis prophylaxis

Adverse effects: Hypokalemia, hyponatremia (most common among diuretics), hyperglycemia, hyperlipidemia, hyperuricemia, impotence, hypercalcemia

K⁺-Sparing Diuretics

Drug	MOA	Dose	Special features
Spironolactone	Aldosterone antagonist (competitive)	25–200 mg/day	Gynecomastia, antiandrogen
Eplerenone	Selective aldosterone antagonist	25–50 mg/day	No gynecomastia
Amiloride	Blocks ENaC directly	5–10 mg/day	No hormonal effects
Triamterene	Blocks ENaC directly	50–100 mg BD	Causes renal stones

Key use: Prevent/treat hypokalemia from loop/thiazide diuretics; heart failure (spironolactone/eplerenone reduce mortality)

Carbonic Anhydrase Inhibitors (Acetazolamide)

MOA: Inhibits CA in PCT → ↓ HCO₃⁻ reabsorption → alkaline diuresis → hyperchloremic metabolic acidosis

Uses:

Glaucoma (drug of choice for chronic open-angle glaucoma; reduces aqueous humor)
Altitude sickness (prophylaxis + treatment)
Epilepsy (absence seizures, adjunct)
Periodic paralysis (hypokalemic type)
Metabolic alkalosis
Cystinuria (alkalinizes urine → ↑ cystine solubility)

Self-limiting: Efficacy lost in 2–3 days due to HCO₃⁻ depletion (acidosis develops)

Osmotic Diuretics (Mannitol)

MOA: Freely filtered, not reabsorbed → osmotically retains water in tubule → large volume of dilute urine

Dose: 1–2 g/kg IV (20% solution)

Uses:

Cerebral edema / raised ICP — drug of choice
Acute congestive glaucoma (IV)
Prophylaxis of ARF (rhabdomyolysis, hemolysis)
Forced diuresis in poisoning

Contraindicated in: Heart failure, pulmonary edema, anuria (initial ECF expansion may worsen these)

Tripathi's "Diuretic Combinations" (High-Yield)

Furosemide + Spironolactone: Cirrhotic ascites — synergistic, K⁺-neutral (standard ratio 2:5, e.g., furosemide 40 mg + spironolactone 100 mg)
Furosemide + Metolazone: Refractory heart failure edema — powerful sequential nephron blockade (monitor closely for electrolyte crash)
HCTZ + Amiloride / Triamterene: Hypertension — thiazide effect with K⁺ preservation (e.g., Moduretic = HCTZ + amiloride)
Acetazolamide + Loop diuretic: Metabolic alkalosis complicating diuretic use

Since KD Tripathi is not in the library, the above is drawn from my training knowledge of the 8th edition. For the exact text, figures, and tables, please refer to your copy of KD Tripathi's Essentials of Medical Pharmacology, Chapter 40 (Diuretics).

This is a shared conversation. Sign in to Orris to start your own chat.